Back to Search Start Over

Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: A multicenter, randomized controlled trial.

Authors :
Liu J
Gao LD
Fu B
Yang HT
Zhang L
Che SQ
Xu Y
Du X
Liu ZC
Xue Y
Lv CX
Huang YH
Wang BH
Gao SX
Xing YF
Yuan XH
Source :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2022 Jun; Vol. 100, pp. 154079. Date of Electronic Publication: 2022 Apr 02.
Publication Year :
2022

Abstract

Backgroud: Zicuiyin (ZCY) decoction created by Xichun Zhang in the Qing dynasty has been used on diabetes mellitus and complications for more than two centuries in China. Huangkui capsule (HKC) is a listed Chinese patent medicine to treat diabetic kidney disease (DKD). To determine whether ZCY is non-inferior to HKC in the treatment of DKD, a multicenter, parallel-control, open-label, randomized clinical trial was conducted.<br />Methods: In this clinical trial, 88 DKD patients were recruited at three centers in Tianjin from January 2018 to December 2019. They were randomized to receive HKC (2.5 g, TID) or ZCY (crude drug amount 75 g, 150 ml, BID) for eight weeks based on routine treatment. The primary outcome was the change of estimated glomerular filtration rate (eGFR). The secondary outcomes included change of serum creatinine (SCr), urinary albumin excretion rate, 24 h urinary protein, urinary albumin-creatinine ratio, glycosylated hemoglobin A1c, symptom scores, and microbiota compositions profiles.<br />Results: The change of eGFR in HKC and ZCY groups were -7.08 ± 24.65 and 2.57 ± 18.49 ml/min/1.73 m <superscript>2</superscript> , respectively (p < 0.05). The 95% lower confidence limit for the difference between the estimated means was 1.93 ml/min/1.73 m <superscript>2</superscript> , establishing the superiority of ZCY. Compared to HKC, ZCY could significantly decrease SCr and symptom scores (p < 0.05). There were no significant differences in other outcomes between the two groups (p > 0.05). ZCY ameliorated gut microbiota dysbiosis, including increased Prevotellaceae and Lactobacillaceae and decreased Enterobacteriales, Clostridiaceae and Micrococcaceae. No severe adverse events were reported in any group.<br />Conclusions: ZCY had better efficacy in improving and protecting kidney function. It would be an alternative option to treat DKD, especially those who decline eGFR and gut microbiota dysbiosis.<br />Trial Registration: Chinese Clinical Trial Registry: ChiCTR-OON-17012076. Registered July 21, 2017.<br /> (Copyright © 2022 Elsevier GmbH. All rights reserved.)

Details

Language :
English
ISSN :
1618-095X
Volume :
100
Database :
MEDLINE
Journal :
Phytomedicine : international journal of phytotherapy and phytopharmacology
Publication Type :
Academic Journal
Accession number :
35413644
Full Text :
https://doi.org/10.1016/j.phymed.2022.154079